Answers are grounded in this paper and cite their sources.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) dapagliflozin and empagliflozin are indicated for heart failure with reduced ejection fraction (HFrEF) for cardiovascular death and heart failure hospitalization risk reduction. Due to the recent nature of these data, prescribing of SGLT2is may be suboptimal.
No takes yet. Share an insight, caveat, or question.
W-O et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: